Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 11/20 | 0.66 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.62 |
| ▸ | NOS2 | P35228 | 2/20 | 0.57 |
| ▸ | NOS1 | P29475 | 2/20 | 0.57 |
| ▸ | NOS3 | P29474 | 1/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.49 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4955426 | 1.00 | BHMT (0.66) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL1285565 | 1.00 | BHMT (0.66) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL18832133 | 0.94 | BHMT (0.69) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL17956289 | 0.93 | BHMT (0.58) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL11575012 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL18832139 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL18832141 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL2367840 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL18832137 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL2367837 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5377 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565194-A1 | ODOR AND COLORANT STABILIZED COMPOSITIONS | Symrise AG (DE) | 2025-06-11 | — | — | EP | claimed |
| EP-4110477-B1 | COMPOSITIONS COMPRISING ONE OR MORE (BIO)-ALKANEDIOLS WITH ANTIOXIDANTS | SYMRISE AG (DE) | 2025-03-19 | — | — | EP | claimed |
| WO-2024102342-A1 | COMBINATION OF A GLUTATHIONE SYNTHESIS INHIBITOR SUCH AS BUTHIONINE SULPHOXIMINE AND AN IMMUNE CHECKPOINT INHIBITOR, PREFERABLY PEMBROLIZUMAB, TO TREAT CANCER, PREFERABLY DRUG-RESISTANT MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2024-05-16 | — | — | WO | claimed |
| US-20240065994-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES OR DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | NICHENAMETLA SAILENDRA NATH (US) | 2024-02-29 | — | — | US | claimed |
| WO-2024040132-A2 | SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2024-02-22 | — | — | WO | claimed |
| WO-2024027931-A1 | ODOR AND COLORANT STABILIZED COMPOSITIONS | SYMRISE AG (DE) | 2024-02-08 | — | — | WO | claimed |
| WO-2024028513-A1 | ODOR AND COLORANT STABILIZED COMPOSITIONS | SYMRISE AG (DE) | 2024-02-08 | — | — | WO | claimed |
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | CELL2IN, INC. (KR) | 2023-12-12 | — | — | US | claimed |
| US-11773060-B2 | Method for synthesis of 9-cis-beta-carotene and formulations thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-10-03 | — | — | US | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| EP-0668933-A4 | USE OF METHIONINASE AS AN ANTITUMOR AGENT IN ANTI-METHIONINE CHEMOTHERAPY. | ANTICANCER INC (US) | 1997-05-21 | — | — | EP | claimed |
| US-5621002-A | HAVING A MODIFIED COMPETITIVE ENZYME ACTIVITY INHBITOR LINKED TO A SPACER-DRUG; ENZYME CLEAVAGE AT A LOWER CONCENTRATION, I.E. LOW MICHAELIS-MENTEN CONSTANT(KM) | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | claimed |
| US-5508031-A | Method for treating biological damage using a free-radial scavenger and interleukin-2 | CETUS ONCOLOGY CORPORATION (US) | 1996-04-16 | — | — | US | claimed |
| EP-0668933-A1 | USE OF METHIONINASE AS AN ANTITUMOR AGENT IN ANTI-METHIONINE CHEMOTHERAPY | ANTICANCER, INC. (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0436642-B1 | PRE-ACTIVATED THERAPEUTIC AGENTS DERIVED FROM PHOTOACTIVE COMPOUNDS | BAYLOR RES FOUND (US) | 1995-04-26 | — | — | EP | claimed |
| WO-1994011535-A1 | USE OF METHIONINASE AS AN ANTITUMOR AGENT IN ANTI-METHIONINE CHEMOTHERAPY | ANTICANCER, INC. (US) | 1994-05-26 | — | — | WO | claimed |
| CN-1084509-A | A kind of cancer sensitizing drug butyl sulfanilic acid and preparation method thereof | SHANGHAI MEDICAL UNIV (CN) | 1994-03-30 | — | — | CN | claimed |
| EP-0269017-B1 | THERAPEUTIC COMBINATION OF FREE-RADICAL SCAVENGER OR METABOLIC INHIBITOR AND BIOLOGICALLY ACTIVE PROTEIN | CETUS ONCOLOGY CORPORATION (US) | 1992-07-29 | — | — | EP | claimed |
| US-4985241-A | URIC ACID, BUTHIONINE SULPHOXIMINE, VITAMIN C | CETUS CORPORATION (US) | 1991-01-15 | — | — | US | claimed |
| EP-0269017-A2 | Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein | CETUS ONCOLOGY CORPORATION (US) | 1988-06-01 | — | — | EP | claimed |